X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs ASTRAZENECA PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA ASTRAZENECA PHARMA GSK PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 62.7 106.4 58.9% View Chart
P/BV x 10.1 15.2 66.4% View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 GSK PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
ASTRAZENECA PHARMA
Mar-14
GSK PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3,8381,285 298.7%   
Low Rs2,637634 415.9%   
Sales per share (Unadj.) Rs354.2189.6 186.8%  
Earnings per share (Unadj.) Rs39.8-0.2 -19,530.4%  
Cash flow per share (Unadj.) Rs42.93.8 1,115.1%  
Dividends per share (Unadj.) Rs30.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs236.968.6 345.2%  
Shares outstanding (eoy) m84.7025.00 338.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.15.1 180.6%   
Avg P/E ratio x81.4-4,712.7 -1.7%  
P/CF ratio (eoy) x75.5249.6 30.3%  
Price / Book Value ratio x13.714.0 97.7%  
Dividend payout %75.40-   
Avg Mkt Cap Rs m274,21623,988 1,143.2%   
No. of employees `0004.71.6 301.3%   
Total wages/salary Rs m4,8301,605 301.0%   
Avg. sales/employee Rs Th6,387.03,040.2 210.1%   
Avg. wages/employee Rs Th1,028.31,029.2 99.9%   
Avg. net profit/employee Rs Th717.1-3.3 -21,962.4%   
INCOME DATA
Net Sales Rs m30,0004,740 632.9%  
Other income Rs m72892 790.7%   
Total revenues Rs m30,7284,832 636.0%   
Gross profit Rs m4,190-130 -3,227.9%  
Depreciation Rs m263101 259.9%   
Interest Rs m00-   
Profit before tax Rs m4,655-139 -3,351.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m457139 329.0%   
Tax Rs m1,7445 34,263.3%   
Profit after tax Rs m3,368-5 -66,169.0%  
Gross profit margin %14.0-2.7 -510.0%  
Effective tax rate %37.5-3.7 -1,022.4%   
Net profit margin %11.2-0.1 -10,454.1%  
BALANCE SHEET DATA
Current assets Rs m16,7422,726 614.1%   
Current liabilities Rs m7,2022,435 295.8%   
Net working cap to sales %31.86.1 517.2%  
Current ratio x2.31.1 207.6%  
Inventory Days Days5274 70.3%  
Debtors Days Days2141 51.0%  
Net fixed assets Rs m8,6351,035 834.1%   
Share capital Rs m84750 1,694.0%   
"Free" reserves Rs m19,222942 2,039.6%   
Net worth Rs m20,0691,716 1,169.5%   
Long term debt Rs m100-   
Total assets Rs m30,0384,156 722.8%  
Interest coverage xNMNM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.01.1 87.6%   
Return on assets %11.2-0.1 -9,154.9%  
Return on equity %16.8-0.3 -5,657.9%  
Return on capital %25.50-  
Exports to sales %05.7 0.0%   
Imports to sales %06.5 0.0%   
Exports (fob) Rs mNA270 0.0%   
Imports (cif) Rs mNA306 0.0%   
Fx inflow Rs m528375 141.0%   
Fx outflow Rs m7,193470 1,529.9%   
Net fx Rs m-6,665-96 6,975.4%   
CASH FLOW
From Operations Rs m2,360-8 -29,135.8%  
From Investments Rs m3,008-146 -2,064.5%  
From Financial Activity Rs m-5,108862 -592.4%  
Net Cashflow Rs m260709 36.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 75.0 67.6%  
Indian inst/Mut Fund % 10.2 0.3 3,400.0%  
FIIs % 23.8 15.7 151.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 9.1 169.2%  
Shareholders   102,036 12,856 793.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   ABBOTT INDIA  ALKEM LABORATORIES  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  ALEMBIC PHARMA  

Compare GSK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Red; PSU & Energy Stocks Decline(01:30 pm)

Indian share markets continued to trade in red during the noon session weak Asian markets. PSU stocks and energy stocks are witnessing majority of the selling activity.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Feb 22, 2018 02:53 PM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - STERLING BIOTECH COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS